TME Pharma

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned. 

GLORIA Overall Survival at 18 months: NOX-A12 Combinations Improve Survival in Chemotherapy-Resistant Incompletely Resected Glioblastoma Patients

Capital increase with rights issue Subscription from November 30 to December 11 More information for shareholders Webinar recording (French)     Fact SheetCorporate Presentation

Press Release 2023, November 28 08:00 a.m. TME Pharma announces the initiation of the listing of preferential subscription rights for fully guaranteed €2.7 million capital increase 2023, November 24 06:00 p.m. TME Pharma launches fully guaranteed €2.7 million preferential rights issue with warrants attached combined with buyback of convertible debt 2023, November 18 08:00 a.m. TME Pharma announces additional data from NOX-A12 combination regimen in brain cancer presented at SNO 2023 Annual Meeting

Events SNO Annual Meeting 2023 November 15 -19 | Vancouver, Canada -download poster Invest Securities Biomed Forum 2024 Aram Mangasarian January 30 | Paris, France 17th Annual European Life Sciences CEO Forum Aram Mangasarian (Speaker) February 28- 29 | Zurich, Switzerland 5th Annual Glioblastoma Development Summit Aram Mangasarian (Panel Speaker) March 26 – 28 | Boston, USA